Malignant Hyperthermia: A Pharmacogenetic Disease of Skeletal and Cardiac Muscle
- 16 May 1974
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 290 (20) , 1140-1142
- https://doi.org/10.1056/nejm197405162902012
Abstract
Malignant hyperthermia was first reported by Denborough in 19621 as a potentially lethal, autosomal dominant syndrome of unknown aetiology. The condition he described consisted of fulminant crises triggered by potent inhalational anesthetic agents, the outstanding features of which were fever, tachycardia, tachypnea and cyanosis. In the few intervening years much has been learned about this remarkable pharmacogenetic disturbance of the skeletal and cardiac muscles.Before anesthesia some members of many, but not all, malignant-hyperthermia-susceptible families have a greater than normal muscle bulk and power. Associated with this generalized muscularity may be localized areas of muscle weakness such as ptosis, kyphoscoliosis, . . .Keywords
This publication has 7 references indexed in Scilit:
- HISTOLOGICAL, HISTOCHEMICAL AND ULTRAMICROSCOPIC FINDINGS IN MUSCLE BIOPSIES FROM CARRIERS OF THE TRAIT FOR MALIGNANT HYPERPYREXIABritish Journal of Anaesthesia, 1973
- Malignant hyperthermia: an investigation of five patientsCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1973
- PROCEEDINGS OF THE ANAESTHETIC RESEARCH SOCIETY UNIVERSITY OF LIVERPOOL MEETING HELD AT IMPERIAL CHEMICAL INDUSTRIES, PHARMACEUTICAL DIVISION, MACCLESFIELD: APRIL 14, 1973British Journal of Anaesthesia, 1973
- Procaine in Malignant HyperpyrexiaBMJ, 1972
- INHERITANCE OF MALIGNANT HYPERPYREXIAThe Lancet, 1972
- Malignant hyperthermia: A statistical reviewCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1970
- ANAESTHETIC DEATHS IN A FAMILYBritish Journal of Anaesthesia, 1962